Metformin vs Rapamycin
Two prescription drugs borrowed for longevity from opposite ends of biology: an old, cheap diabetes tablet versus a transplant immunosuppressant with the field's best animal lifespan data.
Short answer
With human clinical data on both sides, metformin and rapamycin differ mainly in what they are for. Metformin is marketed for longevity, healthspan and metabolic aging; rapamycin is the choice for readers interested in longevity and healthspan (off-label). Both are prescription drugs.
Metformin
An approved diabetes drug with an intriguing longevity hypothesis — but the dedicated aging trial (TAME) is still pending; longevity in healthy people is unproven.
Full Metformin evidence reviewRapamycin
Extends lifespan in mice via mTOR; small human trials (PEARL) address safety, but a longevity benefit in people is unproven.
Full Rapamycin evidence reviewMetformin vs Rapamycin: head to head
- FDA status / approved use
Metformin
Decades-old diabetes drug; taking it for longevity is off-label and unprovenRapamycin
Has a drug label for daily transplant dosing; use for aging is off-label- Marketed for
Metformin
Longevity, healthspan, metabolic agingRapamycin
Longevity, healthspan (off-label)- Outcome areas
Metformin
Longevity / lifespan; Blood sugar / insulin sensitivityRapamycin
Longevity / lifespan- Evidence grade
Metformin
Clinical dataRapamycin
Clinical data- How it works
Metformin
Activates AMPK and reduces mTOR signaling, nutrient-sensing pathways tied to agingRapamycin
Inhibits mTOR, a nutrient-sensing pathway tied to longevity across species- Route and dosing
Metformin
Not establishedRapamycin
Taken off-label in intermittent low doses- Headline human result
Metformin
Observational only: diabetics on metformin survived as long as matched non-diabetics; the TAME outcome trial has not reportedRapamycin
No change in the primary outcome, visceral adiposity, over 48 weeks in the PEARL RCT; gains only in subgroups- Strongest evidence
Metformin
MILES/TAME rationale 2014Metformin evidence reviewPubMed 25041462Rapamycin
mTOR/mouse lifespan, Nature 2009Rapamycin evidence reviewPubMed 19587680- Key safety signal
Metformin
Not establishedRapamycin
Mouth ulcers are the most noticed side effect, even on intermittent regimens- How it is obtained
Metformin
Prescription drugRapamycin
Prescription drug
| Metformin | Rapamycin | |
|---|---|---|
| FDA status / approved use | Decades-old diabetes drug; taking it for longevity is off-label and unproven | Has a drug label for daily transplant dosing; use for aging is off-label |
| Marketed for | Longevity, healthspan, metabolic aging | Longevity, healthspan (off-label) |
| Outcome areas | Longevity / lifespan; Blood sugar / insulin sensitivity | Longevity / lifespan |
| Evidence grade | Clinical data | Clinical data |
| How it works | Activates AMPK and reduces mTOR signaling, nutrient-sensing pathways tied to aging | Inhibits mTOR, a nutrient-sensing pathway tied to longevity across species |
| Route and dosing | Not established | Taken off-label in intermittent low doses |
| Headline human result | Observational only: diabetics on metformin survived as long as matched non-diabetics; the TAME outcome trial has not reported | No change in the primary outcome, visceral adiposity, over 48 weeks in the PEARL RCT; gains only in subgroups |
| Strongest evidence | MILES/TAME rationale 2014Metformin evidence reviewPubMed 25041462 | mTOR/mouse lifespan, Nature 2009Rapamycin evidence reviewPubMed 19587680 |
| Key safety signal | Not established | Mouth ulcers are the most noticed side effect, even on intermittent regimens |
| How it is obtained | Prescription drug | Prescription drug |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
Neither is approved for aging; both are taken off-label for it, and they have never been compared head to head. Metformin's longevity case is an observational survival signal plus MILES, which measured gene-expression changes in muscle and fat rather than any clinical outcome, with TAME, the trial designed to settle the question, still not reported. Rapamycin has the stronger biology, extending lifespan in genetically heterogeneous mice even when started late in life, and PEARL found one year of intermittent dosing generally well-tolerated with modest, mixed healthspan results. It also carries the heavier risk: sirolimus is an immunosuppressant, and the infection risk, impaired wound healing, and lipid and glucose effects on its label come from daily transplant dosing.
Metformin fits if
Metformin is the more conservative off-label choice for someone who has a metabolic reason to be on it anyway and accepts that the longevity claim rests on observational and surrogate data.
Rapamycin fits if
Rapamycin fits only someone working with a physician who wants the strongest animal lifespan evidence in the field and understands it is an immunosuppressant with no proven human aging benefit.
Metformin vs Rapamycin: common questions
- Which has stronger human evidence, metformin or rapamycin?
- Neither clearly. Both have human clinical data. The key source for metformin is MILES/TAME rationale 2014; for rapamycin, it is mTOR/mouse lifespan, Nature 2009.
- What results have metformin and rapamycin shown in people?
- The headline human result for metformin is observational only: diabetics on metformin survived as long as matched non-diabetics; the TAME outcome trial has not reported. In trials, rapamycin showed no change in the primary outcome, visceral adiposity, over 48 weeks in the PEARL RCT; gains only in subgroups.
Key studies behind each
Metformin
- Bannister CA, Holden SE, Jenkins-Jones S, et al. (2014). Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab. PubMed 25041462
- Kulkarni AS, Gubbi S, Barzilai N. (2020). Benefits of Metformin in Attenuating the Hallmarks of Aging. Cell Metab. PubMed 32333835
- Kulkarni AS, Brutsaert EF, Anghel V, et al. (2018). Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults (MILES). Aging Cell. PubMed 29383869
- Barzilai N, Crandall JP, Kritchevsky SB, et al. (2016). Metformin as a Tool to Target Aging. Cell Metab. PubMed 27304507
Rapamycin
- Harrison DE, Strong R, Sharp ZD, et al. (2009). Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. PubMed 19587680
- Mannick JB, Del Giudice G, Lattanzi M, et al. (2014). mTOR inhibition improves immune function in the elderly. Sci Transl Med. PubMed 25540326
- Mannick JB, Morris M, Hockey HP, et al. (2018). TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med. PubMed 29997249
- Moel M, Harinath G, Lee V, et al. (2025). Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY). PubMed 40188830
The full evidence reviews
- Metformin for longevity: TAME, MILES, and the healthspan hypothesis
A provocative survival signal, a credible mechanism, surrogate-level human data — but the definitive outcome trial hasn't reported. An honest grade.
Updated August 2026
- Rapamycin for longevity: the PEARL trial and the human evidence
Gold-standard mouse lifespan data, randomized human trials on an immune surrogate, and a one-year PEARL safety read — but no evidence yet that it extends human healthspan.
Updated August 2026